Eloxx Pharmaceuticals (ELOX) vs. Its Competitors Head to Head Review

Eloxx Pharmaceuticals (NASDAQ:ELOX) is one of 902 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Eloxx Pharmaceuticals to related companies based on the strength of its valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Risk & Volatility

Eloxx Pharmaceuticals has a beta of -1862.26, indicating that its share price is 186,326% less volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals’ competitors have a beta of -3.15, indicating that their average share price is 415% less volatile than the S&P 500.

Profitability

This table compares Eloxx Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Eloxx Pharmaceuticals Competitors	-2,309.62%	-223.14%	-17.45%

Analyst Recommendations

This is a summary of current recommendations and price targets for Eloxx Pharmaceuticals and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	1	0	2	1	2.75
Eloxx Pharmaceuticals Competitors	7573	13639	25435	998	2.42

Eloxx Pharmaceuticals presently has a consensus price target of $41.50, suggesting a potential upside of 163.49%. As a group, “Pharmaceuticals” companies have a potential upside of 33.39%. Given Eloxx Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts plainly believe Eloxx Pharmaceuticals is more favorable than its competitors.

Earnings and Valuation

This table compares Eloxx Pharmaceuticals and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Eloxx Pharmaceuticals	N/A	-$5.99 million	-10.23
Eloxx Pharmaceuticals Competitors	$3.51 billion	$3.15 billion	551.06

Eloxx Pharmaceuticals’ competitors have higher revenue and earnings than Eloxx Pharmaceuticals. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are owned by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Eloxx Pharmaceuticals beats its competitors on 7 of the 13 factors compared.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.